These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 11677135)
1. Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. Liu KG; Lambert MH; Leesnitzer LM; Oliver W; Ott RJ; Plunket KD; Stuart LW; Brown PJ; Willson TM; Sternbach DD Bioorg Med Chem Lett; 2001 Nov; 11(22):2959-62. PubMed ID: 11677135 [TBL] [Abstract][Full Text] [Related]
2. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385 [TBL] [Abstract][Full Text] [Related]
4. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620 [TBL] [Abstract][Full Text] [Related]
5. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466 [TBL] [Abstract][Full Text] [Related]
13. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Brown PJ; Stuart LW; Hurley KP; Lewis MC; Winegar DA; Wilson JG; Wilkison WO; Ittoop OR; Willson TM Bioorg Med Chem Lett; 2001 May; 11(9):1225-7. PubMed ID: 11354382 [TBL] [Abstract][Full Text] [Related]
18. [Study on 3D-QSAR of PPAR gamma agonists with thiazolidinedione and arylketo-acid moieties]. Yi X; Guo ZR Yao Xue Xue Bao; 2001 Apr; 36(4):262-8. PubMed ID: 12580053 [TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. Baylis C; Atzpodien EA; Freshour G; Engels K J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039 [TBL] [Abstract][Full Text] [Related]
20. Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists. Adams AD; Yuen W; Hu Z; Santini C; Jones AB; MacNaul KL; Berger JP; Doebber TW; Moller DE Bioorg Med Chem Lett; 2003 Mar; 13(5):931-5. PubMed ID: 12617924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]